DDX3Y is a DEAD-box RNA helicase gene located on the Y chromosome, playing a pivotal role in male sex determination and spermatogenesis. It is part of the DDX family of helicases, which are involved in various aspects of RNA metabolism, including transcription, splicing, mRNA export, and decay. DDX3Y is essential for the normal development of male gonads and is implicated in the regulation of gene expression by modulating the RNA secondary structure, thereby facilitating the assembly of ribonucleoprotein complexes. Its expression is highly specific to testicular tissue, where it contributes to the maturation of sperm cells and influences male fertility. Beyond its roles in normal physiological processes, DDX3Y has been studied for its involvement in Y chromosome-linked disorders and its expression in certain male-specific cancers, underscoring its significance in both developmental biology and disease.
The inhibition of DDX3Y's function can be achieved through several molecular strategies that target its helicase activity or its expression. One approach involves the use of small molecule inhibitors that specifically bind to the ATPase or helicase domains of DDX3Y, obstructing its ability to unwind RNA substrates. This inhibition could directly impact RNA processing events and gene regulation mechanisms essential for spermatogenesis and influence the progression of Y-linked disorders or cancers where DDX3Y is aberrantly expressed. Alternatively, RNA interference (RNAi) technology can be utilized to reduce DDX3Y expression by promoting the degradation of its mRNA, thereby decreasing the protein levels and limiting its functional involvement in RNA metabolism. Such targeted inhibition strategies offer valuable tools for dissecting the biological functions of DDX3Y and exploring its roles in male fertility, development, and disease. By understanding the mechanisms that regulate DDX3Y activity and its contributions to cellular processes, researchers can further elucidate the complex network of genes involved in Y chromosome function and male-specific pathologies.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib might indirectly inhibit DDX3Y by targeting the MAPK/ERK pathway, affecting downstream factors that interact with DDX3Y in cancer-related processes. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib could indirectly inhibit DDX3Y by modulating the PDGFR pathway, which may impact DDX3Y's involvement in cellular processes. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib may indirectly inhibit DDX3Y through the EGFR pathway, influencing downstream signaling events related to DDX3Y functions. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib might indirectly inhibit DDX3Y by targeting the MAPK/ERK pathway, affecting downstream factors associated with DDX3Y's role in cancer. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib could indirectly inhibit DDX3Y by modulating the EGFR pathway, which might impact DDX3Y's involvement in cellular processes. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib may indirectly inhibit DDX3Y through its influence on the NF-κB pathway, which could affect DDX3Y's interactions within this pathway. | ||||||